Nanalysis Scientific Corp. Announces $2.5 Million Private Placement Offering for Debt Reduction

Nanalysis Announces $2.5 Million Private Placement

On December 8, 2025, Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) made a significant announcement regarding its financial strategy. The Calgary-based company revealed plans to initiate a non-brokered private placement, aiming to raise up to $2.5 million through the issuance of 16,666,667 units at a price of $0.15 per unit. This move is seen primarily as a means to assist in reducing outstanding debts, which is a crucial step in strengthening the company’s financial position.

Structure of the Offering

Each unit in this offering will comprise one common share of Nanalysis and one-half of a share purchase warrant. Investors will benefit from the warrants, which will allow them to purchase additional shares at an exercise price of $0.20 per share for up to two years from the closing date of the offering. This structure aims to provide an attractive entry for new investors while offering current shareholders an opportunity to increase their stake in the company.

The warrants come with an acceleration provision; if the company’s shares reach a closing price of $0.30 on the TSX Venture Exchange for ten consecutive trading days, Nanalysis has the option to accelerate the expiry of the warrants. This provision is designed to strengthen shareholder engagement and could reflect positively on the company’s market performance.

Regulatory Considerations and Timeline

The completion of this offering is contingent upon approval from the TSX Venture Exchange and satisfaction of standard closing conditions. Nanalysis anticipates the first closing of the offering around December 15, 2025. It’s important to note that all securities issued will be subject to a statutory holding period of four months plus one day.

This offering does not constitute a public solicitation or a direct offer to sell securities in the United States, as the offered shares have not been registered under the 1933 Securities Act and may not be sold without proper exemptions. As such, Nanalysis clarifies that high standards of regulatory compliance govern its operations in order to maintain investor confidence and market integrity.

Company Overview

Nanalysis Scientific Corp. is at the forefront of technology, specializing in the development and manufacturing of portable Nuclear Magnetic Resonance (NMR) spectrometers. These devices serve a wide range of industries, including pharmaceuticals, biotechnology, energy, food safety, material analysis, and security applications. Moreover, Nanalysis also runs a service division responsible for maintaining both its own products and third-party equipment.

A notable contract with the Canadian Air Transport Security Authority (CATSA) underpins this service division, where the company is responsible for maintaining security scanners at over 80 Canadian airports, ensuring rigorous safety standards are upheld in the aviation sector.

Future Outlook

While the private placement underscores Nanalysis's commitment to maintaining control over its financial obligations, investors and analysts alike will be watching closely to ensure that these funds are deployed effectively and contribute to enhancing the company’s operational capabilities. The second half of 2025 holds promise, given the company’s innovative approach to NMR technology and its strategic opportunities within the marketplace.

Nanalysis continues to exemplify how scientifically driven companies can remain agile in the face of changing market demands while seeking to optimize their capital structures. As the company embarks on this new fundraising initiative, stakeholders are keenly aware that sound financial practices will determine its long-term success and sustainability in a competitive industry.